CTOs on the Move

Sermonix Pharmaceuticals

www.sermonixpharma.com

 
Sermonix Pharmaceuticals is an Ohio LLC privately held biotechnology company with a targeted focus towards bringing female-specific oncology products through proof of concept, preclinical, and clinical development with a clear regulatory pathway in place. Sermonix was founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women`s health, menopause and selective estrogen receptor modulators, or SERM therapy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Sermonix Pharmaceuticals raised $26M on 07/31/2019

Similar Companies

Dendritic NanoTechnologies

Dendritic NanoTechnologies is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brain TunnelGenix Technologies Corp

Brain TunnelGenix Technologies Corp is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FOB Synthesis

FOB Synthesis is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Singular Genomics

Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.

resTORbio

resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.